Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The company is eligible for 12 months exclusivity from launch
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The aim is to create new genomics solutions that could combat cancer and advance market access
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
